SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated cancer target, being overexpressed in several tumour types including synovial sarcomas, oesophageal, liver, gastric, prostate and lung cancers.

Cancer Research UK and Scancell have entered into a Clinical Development Partnership to develop the SCIB2 vaccine for the treatment of patients with solid tumours, including non-small cell lung cancer (NSCLC), in which CRUK will manage and conduct a Phase1/2 clinical trial of SCIB2 in combination with an anti-PD1 immune checkpoint inhibitor. As for the SCIB1 vaccine, the synergistic potential of SCIB2 with a checkpoint inhibitor has been confirmed in preclinical tumour models.